The Use of Sedation Drugs in the Procedure of Administering Surfactant Without Intubation (LISA/MIST) (LISA KGS)
Primary Purpose
Neonatal Respiratory Distress Syndrome, Gestational Age Conditions
Status
Recruiting
Phase
Phase 1
Locations
Poland
Study Type
Interventional
Intervention
Ketamine
Glucose
Sponsored by
About this trial
This is an interventional supportive care trial for Neonatal Respiratory Distress Syndrome focused on measuring LISA, LISA sedation, MIST, MIST sedation, Ketamine, Glucose, RDS, Newborn
Eligibility Criteria
Inclusion Criteria:
- Infant with established Respiratory Distress Syndrome (RDS) or at risk for RDS
- Gestational age 28 0/7 - 32 6/7 weeks
- Non-invasive respiratory support with nasal CPAP (incl. BiPAP) or NIPPV
- Need for administration of exogenous surfactant
Exclusion Criteria:
- Need for intubation and mechanical ventilation at the Delivery Room
- Infant with clinically significant maxillo-facial, tracheal or pulmonary malformations
Sites / Locations
- Uniwersyteckie Centrum Zdrowia Kobiety NoworodkaRecruiting
Arms of the Study
Arm 1
Arm 2
Arm Type
Experimental
Active Comparator
Arm Label
Ketamine sedated group
Glucose sedated group
Arm Description
30 randomized patients will receive Ketamine 1 mg/kg , I.V. 2 minutes before LISA
30 patients will receive Glucose 30% 1 mL, sublingually, 2 minutes before LISA
Outcomes
Primary Outcome Measures
Assessment of patient sedation
Assessment of patient sedation change before and after LISA using COMFORT scale
Assessment of patient sedation
Assessment of patient sedation change before and after LISA using FANS scale
Comparing ketamine and glucose
Comparison of the effectiveness of sedation with ketamine and glucose using the FANS scale scores. The FANS scale ranges from 0 points at minimum to 10 points at maximum. The higher the score, the lower the sedation.
Comparing ketamine and glucose
Comparison of the effectiveness of sedation with ketamine and glucose using the COMFORT scale scores. The Comfort scale ranges from 8 points at minimum, to 40 at maximum. The higher the score, the lower the sedation level.
Secondary Outcome Measures
Frequency of complications
Monitoring the possible side effects of used drugs
Full Information
NCT ID
NCT04409665
First Posted
May 20, 2020
Last Updated
January 16, 2022
Sponsor
Medical University of Warsaw
1. Study Identification
Unique Protocol Identification Number
NCT04409665
Brief Title
The Use of Sedation Drugs in the Procedure of Administering Surfactant Without Intubation (LISA/MIST)
Acronym
LISA KGS
Official Title
The Use of Sedation Drugs in the Procedure of Administering Surfactant Without Intubation (LISA/MIST): a Randomized Study Comparing Intravenous Ketamine With Sublingual 30% Glucose
Study Type
Interventional
2. Study Status
Record Verification Date
January 2022
Overall Recruitment Status
Recruiting
Study Start Date
January 1, 2020 (Actual)
Primary Completion Date
March 31, 2022 (Anticipated)
Study Completion Date
April 30, 2022 (Anticipated)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Medical University of Warsaw
4. Oversight
Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No
5. Study Description
Brief Summary
The purpose of this study is to evaluate the efficacy and impact of intravenous ketamine or sublingual 30% glucose as sedation drugs used in preterm premature babies during the LISA procedure. The second goal is to compare the frequency of complications during LISA with both premedication regimens.
Detailed Description
All infants fulfilling the inclusion criteria during the 12 months recruitment window will potentially be enrolled in this randomized controlled trial of LISA premedication. Written informed consent will be acquired from parents or legal guardians. After the consent, infants needing the LISA will receive premedication as follows: caffeine citrate according to the clinical routine at study site, and randomly, either ketamine or sublingual glucose 30%. This study is a pilot study and 60 patients that will be randomized 1:1. Ketamine will be given in slow intravenous injection over 60 seconds. Glucose 30% will be given sublingually in the volume of 1 mL. After two minutes (from the end of administration of the study drug or reference drug), laryngoscopy will be started. To assess the effectiveness of both types of sedation, patients will be assessed using two pain assessment scales - the COMFORT scale and the FANS scale. 10 minutes before the procedure, the first assessment in the COMFORT and FANS scales will take place. The next assessment on both scales will take place during the procedure.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Neonatal Respiratory Distress Syndrome, Gestational Age Conditions
Keywords
LISA, LISA sedation, MIST, MIST sedation, Ketamine, Glucose, RDS, Newborn
7. Study Design
Primary Purpose
Supportive Care
Study Phase
Phase 1
Interventional Study Model
Parallel Assignment
Model Description
60 infants randomized 1:1 to receive ketamine or glucose
Masking
None (Open Label)
Allocation
Randomized
Enrollment
60 (Anticipated)
8. Arms, Groups, and Interventions
Arm Title
Ketamine sedated group
Arm Type
Experimental
Arm Description
30 randomized patients will receive Ketamine 1 mg/kg , I.V. 2 minutes before LISA
Arm Title
Glucose sedated group
Arm Type
Active Comparator
Arm Description
30 patients will receive Glucose 30% 1 mL, sublingually, 2 minutes before LISA
Intervention Type
Drug
Intervention Name(s)
Ketamine
Intervention Description
Patient will be sedated using Ketamine 2 minutes before the LISA procedure. 10 minutes prior the procedure and during the procedure the patient's pain and/or discomfort will be evaluated using COMFORT and FANS scales
Intervention Type
Drug
Intervention Name(s)
Glucose
Intervention Description
Patient will be sedated using Glucose 2 minutes before the LISA procedure. 10 minutes prior the procedure and during the procedure the patient's pain and/or discomfort will be evaluated using COMFORT and FANS scales
Primary Outcome Measure Information:
Title
Assessment of patient sedation
Description
Assessment of patient sedation change before and after LISA using COMFORT scale
Time Frame
First assessment 10 minutes before procedure, second during the procedure
Title
Assessment of patient sedation
Description
Assessment of patient sedation change before and after LISA using FANS scale
Time Frame
First assessment 10 minutes before procedure, second during the procedure
Title
Comparing ketamine and glucose
Description
Comparison of the effectiveness of sedation with ketamine and glucose using the FANS scale scores. The FANS scale ranges from 0 points at minimum to 10 points at maximum. The higher the score, the lower the sedation.
Time Frame
Comparing the scores through study completion, an average of two years
Title
Comparing ketamine and glucose
Description
Comparison of the effectiveness of sedation with ketamine and glucose using the COMFORT scale scores. The Comfort scale ranges from 8 points at minimum, to 40 at maximum. The higher the score, the lower the sedation level.
Time Frame
Comparing the scores through study completion, an average of two years
Secondary Outcome Measure Information:
Title
Frequency of complications
Description
Monitoring the possible side effects of used drugs
Time Frame
During the procedure
10. Eligibility
Sex
All
Minimum Age & Unit of Time
1 Minute
Maximum Age & Unit of Time
4 Months
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Infant with established Respiratory Distress Syndrome (RDS) or at risk for RDS
Gestational age 28 0/7 - 32 6/7 weeks
Non-invasive respiratory support with nasal CPAP (incl. BiPAP) or NIPPV
Need for administration of exogenous surfactant
Exclusion Criteria:
Need for intubation and mechanical ventilation at the Delivery Room
Infant with clinically significant maxillo-facial, tracheal or pulmonary malformations
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Tomasz Piotr Pomianek, MD
Phone
502536300
Ext
+48
Email
tomek.pomianek@gmail.com
First Name & Middle Initial & Last Name or Official Title & Degree
Paweł Krajewski, MD, PhD
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Paweł Krajewski, MD, PhD
Organizational Affiliation
Medical University of Warsaw
Official's Role
Principal Investigator
Facility Information:
Facility Name
Uniwersyteckie Centrum Zdrowia Kobiety Noworodka
City
Warsaw
State/Province
Mazowieckie
ZIP/Postal Code
02-015
Country
Poland
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Tomasz Pomianek, MD
Phone
502536300
Ext
+48
Email
tomek.pomianek@gmail.com
First Name & Middle Initial & Last Name & Degree
Paweł Krajewski, PhD, MD
Email
pawelkrajewski@outlook.com
12. IPD Sharing Statement
Plan to Share IPD
Yes
IPD Sharing Plan Description
All of the individual participant data collected during the trial will be available, after de-identification. The study protocol will also be available. These documents will be accessible to anyone who provides a methodologically sound proposal immediately following publication with no end date.
IPD Sharing Time Frame
Immediately following publication. No end date.
IPD Sharing Access Criteria
Anyone who provides a methodologically sound proposal.
Citations:
PubMed Identifier
24524456
Citation
McPherson C, Grunau RE. Neonatal pain control and neurologic effects of anesthetics and sedatives in preterm infants. Clin Perinatol. 2014 Mar;41(1):209-27. doi: 10.1016/j.clp.2013.10.002. Epub 2013 Dec 17.
Results Reference
background
PubMed Identifier
30635595
Citation
Kurepa D, Perveen S, Lipener Y, Kakkilaya V. The use of less invasive surfactant administration (LISA) in the United States with review of the literature. J Perinatol. 2019 Mar;39(3):426-432. doi: 10.1038/s41372-018-0302-9. Epub 2019 Jan 11.
Results Reference
background
PubMed Identifier
29532502
Citation
Bourgoin L, Caeymaex L, Decobert F, Jung C, Danan C, Durrmeyer X. Administering atropine and ketamine before less invasive surfactant administration resulted in low pain scores in a prospective study of premature neonates. Acta Paediatr. 2018 Jul;107(7):1184-1190. doi: 10.1111/apa.14317. Epub 2018 Apr 16.
Results Reference
background
PubMed Identifier
26907795
Citation
Dekker J, Lopriore E, Rijken M, Rijntjes-Jacobs E, Smits-Wintjens V, Te Pas A. Sedation during Minimal Invasive Surfactant Therapy in Preterm Infants. Neonatology. 2016;109(4):308-13. doi: 10.1159/000443823. Epub 2016 Feb 24.
Results Reference
background
PubMed Identifier
28734732
Citation
McPherson C, Inder T. Perinatal and neonatal use of sedation and analgesia. Semin Fetal Neonatal Med. 2017 Oct;22(5):314-320. doi: 10.1016/j.siny.2017.07.007. Epub 2017 Jul 19.
Results Reference
background
PubMed Identifier
27087155
Citation
Allegaert K, van den Anker JN. Neonatal pain management: still in search for the Holy Grail. Int J Clin Pharmacol Ther. 2016 Jul;54(7):514-23. doi: 10.5414/CP202561.
Results Reference
background
PubMed Identifier
30716788
Citation
Fernandez C, Boix H, Camba F, Comunas JJ, Castillo F. Less Invasive Surfactant Administration in Spain: A Survey Regarding Its Practice, the Target Population, and Premedication Use. Am J Perinatol. 2020 Feb;37(3):277-280. doi: 10.1055/s-0039-1678534. Epub 2019 Feb 4.
Results Reference
background
PubMed Identifier
22379381
Citation
Barrington K. Premedication for endotracheal intubation in the newborn infant. Paediatr Child Health. 2011 Mar;16(3):159-71. doi: 10.1093/pch/16.3.159.
Results Reference
background
PubMed Identifier
19221401
Citation
Milesi C, Cambonie G, Jacquot A, Barbotte E, Mesnage R, Masson F, Pidoux O, Ferragu F, Thevenot P, Mariette JB, Picaud JC. Validation of a neonatal pain scale adapted to the new practices in caring for preterm newborns. Arch Dis Child Fetal Neonatal Ed. 2010 Jul;95(4):F263-6. doi: 10.1136/adc.2008.144758. Epub 2009 Feb 16.
Results Reference
background
Learn more about this trial
The Use of Sedation Drugs in the Procedure of Administering Surfactant Without Intubation (LISA/MIST)
We'll reach out to this number within 24 hrs